Thank you for your interest! We look forward to seeing you at the event on September 20, 2011!

Speakers Bios:

Bruce Zutler

Bruce Zutler is a recognized authority in the areas of new product development and global product manufacturing.  He is co-founder and Chief Executive Officer of MCI Products Group, Inc., an internationally attuned company that has been providing creative, strategic and tangible finished product solutions for over 25 years.  Prior to his assuming the role of CEO at MCI in 1994, Bruce held product marketing and management positions with leading consumer product companies including The Franklin Mint, Playtex and Wyeth.  He has authored several international patents and trademarks and has been directly responsible for bringing hundreds of successful new products to market, worldwide. 

Bruce has applied 25+ years of “hands-on” experience to build results driven teams across geographic boarders and cultural boundaries.  Under his leadership, MCI has created, manufactured or licensed a vast array of products in a variety of materials, technologies and processes that can be found in virtually every major retailer in the US.  MCI’s clients represent start-up ventures as well as international companies in the building products (flooring & lighting), housewares, hardware, stationary, technology and medical products industries, including such name brands as General Electric, Bed Bath & Beyond, Avon, 1-800-FLOWERS, Proctor & Gamble, Waterford/Wedgwood and Polo/Ralph Lauren.

Mr. Zutler has served as Co-Chairman of the International Trade Committee of the Hauppauge Industrial Association, is currently Board Member of the Inventors’ Association of Manhattan, and has been a guest on radio talk shows,  been quoted in Business Week and The New York Enterprise Report.

Yunling Ren, Esq, Ph.D.

Dr. Yunling Ren is a patent lawyer with over 15 years of practice experience in both the US and China with specialty in life science. 

Dr. Ren is currently a partner at Lung Tin International Intellectual Property Agent, Ltd, Beijing, China, with a focus on cross border patent prosecution, IP licensing and litigation.  In addition to counseling US companies on IP matters in China, Dr. Ren represents Chinese pharmaceutical companies seeking patent protection and conducting clinical trials in the U.S., and advises a Chinese State owned investment organization in the acquisition of IP rights to bio-pharmaceutical products from the U.S. and drug development in China.

Prior to joining Lung Tin, Dr. Ren was an in-house senior patent counsel to Johnson & Johnson in the pharmaceutical area, where she managed a worldwide patent portfolio, with responsibilities including strategic planning, procurement and enforcement of product related patents, due diligence and negotiations concerning licensing and acquisition activities, and counseling internal clients on all IP matters.

Dr. Ren previously practiced IP law at New York City law firms.  She has a JD from New York Law School, Ph.D. in Biochemistry from City University of New York (CUNY), M.S. in Biochemistry from Beijing Agricultural University, Beijing, China, and B.S. in Biology from Beijing Teacher's College, Beijing, China. 

Howard Jiang, Esq

Mr. Jiang is a corporate partner in the New York office of Troutman Sanders., specialized in mergers and acquisitions and securities work both in domestic and trans-border transactions.

On the merger and acquisition front, Mr. Jiang has advised many companies in their acquisition and sale of equity interests and assets, forming and dissolving strategic alliances, joint ventures and special arrangements in the U.S. and overseas.  He has advised clients in both public and private mergers and acquisitions, represented many U.S. and foreign companies on investment projects in Asia and China in particular as well as companies from the Asia Pacific region in their investments in the U.S. and overseas.  On the securities front, Mr. Jiang has represented many domestic and foreign issuers in various equity and debt instruments offerings and listing on various capital markets, as well as many leading investment banks in their underwriting activities involving domestic and foreign issuers.  Key transactions Mr. Jiang has advised on and represented include

•        Owens Corning in its $800 million asset disposition;

•        Fresenius in acquisition of companies in four countries;

•        American Standard strategic investment in China.

•        CS First Boston in underwriting the $330 million IPO of Shandong Huaneng Power, the first Chinese company to be listed on the New York Stock Exchange;

•        PaineWebber in the $120 million IPO of Advanced Communications Group;

•        Chinese companies listed in U.S.

  o   General Steel Holdings Inc. (GSI)

  o   HQ Sustainable Maritime Industries, Inc.(HQS)

  o   China Housing  and Land Development, Inc.(CHLN)

  o   Rodobo International Inc.(RDBO)

  o   China XD Plastics Company Ltd.(CXDC)

  o   China Gengsheng Mineral Minerals, Inc.(CHGS)

Jie Xiu, Esq

Jie Xiu is an attorney of the Troutman Sanders LLP’s Corporate Group.  Ms. Xiu focuses on mergers and acquisitions and corporate securities. 

On the merger and acquisition front, Jie regularly represents clients in their acquisition and sale of equity interests and assets, joint ventures and a broad spectrum of corporate and business matters. On the securities front, Jie has represented numerous domestic and foreign issuers in various public and private offerings of debt and equity securities, listing on various capital markets, and the Securities Exchange Act compliance.  Jie has extensive experience with American, Canadian, European and Chinese companies with their M&A and corporate finance projects, and advises her clients regularly on U.S. securities laws compliance.  She was named as New York “Rising Star” in Corporate and Business section by New York Super Lawyer Magazine-Metro Edition (2011) 

Key transactions Ms. Xiu has represented include

·        $119.50 million initial public offering of a radiotherapy and diagnostic imaging equipment manufacturer

·        a private equity fund in its $150 million private placement

·        a multinational Canadian company in its issuance of (1) $ 413.0 million 13.75% Senior Secured Notes; (2) $292.8 million 15.5% Senior Notes; (3) $350 million 8.0% Convertible Notes; and (4) $400 million Senior Term Loan

·        Cross-border merger between two major biopharmaceutical companies in U.S. and China

·        Numerous Chinese companies in IPOs, reverse mergers and PIPE offering in conjunction with reverse mergers in the U.S.,

·        Chinese companies in their main board listing application and capital raising through S-1, S-3 public offerings and PIPEs